Open Access

A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights

Xing Li

Xing Li

College of Automation Engineering, Nanjing University of Aeronautics and AstronauticsNan Jing, China
Search for this author on
Sciendo|Google Scholar
Li, Xing
, 
Kaida Liu

Kaida Liu

College of Automation Engineering, Nanjing University of Aeronautics and AstronauticsNan Jing, China
Search for this author on
Sciendo|Google Scholar
Liu, Kaida
, 
Lidong Xing

Lidong Xing

College of Automation Engineering, Nanjing University of Aeronautics and AstronauticsNan Jing, China
Search for this author on
Sciendo|Google Scholar
Xing, Lidong
 and 
Boris Rubinsky

Boris Rubinsky

Department of Mechanical Engineering, University of California BerkeleyBerkeley, United States of America
Search for this author on
Sciendo|Google Scholar
Rubinsky, Boris
  
Sep 04, 2023
A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights's Cover Image
About this article
Previous Article
Next Article
Cite
Download Cover
Article Category: Review
Published Online: Sep 04, 2023
Page range: 279 - 291
Received: Jul 20, 2023
Accepted: Aug 04, 2023
DOI: https://doi.org/10.2478/raon-2023-0044
Keywords
© 2023 Xing Li et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

FIGURE 1.

The process of TTFields clinical trials on typical tumor types.
The process of TTFields clinical trials on typical tumor types.

FIGURE 2.

Clinical trials of TTFields treatment on glioblastoma multiforme (GBM)EF-11= controlled randomized phase III trial EF-11; EF-14 = phase III trial EF-14; OS = overall survival; PFS = progression-free survival; TMZ = temozolomide
Clinical trials of TTFields treatment on glioblastoma multiforme (GBM)EF-11= controlled randomized phase III trial EF-11; EF-14 = phase III trial EF-14; OS = overall survival; PFS = progression-free survival; TMZ = temozolomide

FIGURE 3.

Clinical trials of TTFields treatment on malignant pleural mesothelioma and non-small cell lung cancer (NSCLC).EF-15 phase I/II = clinical trial NCT00749346; LUNAR = clinical trial NCT02973789; OS = overall survival; PFS = progression-free survival; STELLAR = clinical trial NCT 02397928
Clinical trials of TTFields treatment on malignant pleural mesothelioma and non-small cell lung cancer (NSCLC).EF-15 phase I/II = clinical trial NCT00749346; LUNAR = clinical trial NCT02973789; OS = overall survival; PFS = progression-free survival; STELLAR = clinical trial NCT 02397928

FIGURE 4.

Clinical trials of TTFields treatment on platinum-resistant ovarian cancer (PROC), pancreatic adenocarcinoma (PAC) and hepatocellular carcinoma (HCC).AEs = adverse events; INNOVATE = a phase I/II clinical trial (EF-22, NCT02244502) and a phase III randomized controlled clinical trial (EF-28, NCT03940196); OS = overall survival; QoL = quality of life (QoL); PANOVA = a phase I/II clinical trial (EF-20, NCT01971281) and a larger randomized clinical phase III (EF-27, NCT03377491); PFS = progression-free survival
Clinical trials of TTFields treatment on platinum-resistant ovarian cancer (PROC), pancreatic adenocarcinoma (PAC) and hepatocellular carcinoma (HCC).AEs = adverse events; INNOVATE = a phase I/II clinical trial (EF-22, NCT02244502) and a phase III randomized controlled clinical trial (EF-28, NCT03940196); OS = overall survival; QoL = quality of life (QoL); PANOVA = a phase I/II clinical trial (EF-20, NCT01971281) and a larger randomized clinical phase III (EF-27, NCT03377491); PFS = progression-free survival

FIGURE 5.

Researches on potential mechanisms of TTFields action.
Researches on potential mechanisms of TTFields action.
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed